Pharmacokinetics, safety, and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial

BACKGROUND: The poly(ADP-ribose) polymerase (PARP) inhibitor olaparib potentiated radiation and temozolomide (TMZ) chemotherapy in preclinical glioblastoma models but brain penetration was poor. Clinically, PARP inhibitors exacerbate the hematological side effects of TMZ. The OPARATIC trial was cond...

Descripción completa

Detalles Bibliográficos
Autores principales: Hanna, Catherine, Kurian, Kathreena M, Williams, Karin, Watts, Colin, Jackson, Alan, Carruthers, Ross, Strathdee, Karen, Cruickshank, Garth, Dunn, Laurence, Erridge, Sara, Godfrey, Lisa, Jefferies, Sarah, McBain, Catherine, Sleigh, Rebecca, McCormick, Alex, Pittman, Marc, Halford, Sarah, Chalmers, Anthony J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Clinical Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7746945/
https://www.ncbi.nlm.nih.gov/pubmed/32347934
http://dx.doi.org/10.1093/neuonc/noaa104

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7746945/
https://www.ncbi.nlm.nih.gov/pubmed/32347934
http://dx.doi.org/10.1093/neuonc/noaa104

Ejemplares similares